Joint Venture Business in Regenerative Medical Products with JCR Pharmaceuticals
First written in FY2023-Q3. 1 of 3 entries say "Restated". Latest entry: FY2024-Q3.
1 other company's latest entry also says "Advanced".
- FY2024-Q3AdvancedAnnual report
「The addition of induced regulatory T cells (JB-101) to AlliedCel's existing business will enable the provision of appropriate treatment opportunities to patients through regenerative medicine products at an earlier stage.」
For AlliedCel, the joint venture with JCR Pharmaceuticals, decided that it would undertake the domestic manufacturing and marketing of regenerative medicine products using JB-101 under a license agreement with JUNTEN BIO, thereby expanding the scope of its existing business. - FY2023RestatedAnnual report
「October 2022: The Company and JCR Pharmaceuticals Co.,Ltd. jointly established AlliedCel Co., Ltd. to conduct research and development, manufacturing and sales of regenerative medicine products using stem cells, including hematopoietic stem cells, and other cells.」
Reiterates the research and development, manufacturing and sales of regenerative medicine products by AlliedCel, the joint venture with JCR Pharmaceuticals. - FY2023-Q3First statedAnnual report
「In addition, the Company and JCR Pharmaceuticals Co.,Ltd. established a joint venture to conduct research and development, manufacturing and sales of regenerative medicine products using a wide variety of cells, including stem cells, with the aim of bringing regenerative and cellular medicine into practical use. Regenerative and cellular medicine offers a range of possibilities in areas that have been difficult to address using conventional chemically synthesized small-molecule drugs and biopharmaceuticals. Going forward, we will strengthen efforts toward early commercialization, with the aim of providing patients with appropriate treatment opportunities and improving outcomes through regenerative medicine products.」
Established a joint venture with JCR Pharmaceuticals Co.,Ltd. to conduct research and development, manufacturing and sales of regenerative medicine products using stem cells and other cells, and began efforts aimed at bringing regenerative and cellular medicine into practical use and achieving early commercialization.